Arvinas, Inc. (ARVN) News

Arvinas, Inc. (ARVN)

Today's Latest Price: $20.91 USD

1.01 (-4.61%)

Updated Oct 30 4:00pm

Add ARVN to Watchlist
Sign Up

Overall POWR Rating


POWR Components:

 Trade Grade  Buy & Hold Grade  Peer Grade  Industry Rank


Industry Rank:

Ranked of 240 in Medical - Pharmaceuticals

See all "A" rated Strong Buy stocks

Filter ARVN News Items

ARVN News Results

Event/Time Symbol Company News Detail Start End Change POWR Rating
Loading, please wait...

Latest ARVN News From Around the Web

Below are the latest news stories about Arvinas Inc that investors may wish to consider to help them evaluate ARVN as an investment opportunity.

ESSA's Novel Prostate Cancer Treatment In Clinical Trial: Pfizer Is New Lead Investor

ESSA Pharma Inc. (NASDAQ:EPIX) [TSX-V: EPI] is a Canadian/U.S. clinical-stage pharmaceutical company which recently began Phase 1 clinical trials for its lead drug EPI-7386, a novel treatment for men with castration-resistant prostate cancer ("CRPC") where the cancer is progressing despite the men having been treated with current standard of care...

Steven Goldman on Seeking Alpha | August 19, 2020

IPO Update: Kymera Therapeutics Readies $125 Million IPO

Quick Take Kymera Therapeutics (KYMR) intends to raise $125 million from the sale of its common stock in an IPO, according to an amended registration statement. The company is advancing treatment candidates for skin and immune system conditions. KYMR is still some time away from beginning Phase 1 safety trials...

Donovan Jones on Seeking Alpha | August 17, 2020

The Arvinas (NASDAQ:ARVN) Share Price Has Gained 30% And Shareholders Are Hoping For More

The last three months have been tough on Arvinas, Inc. (NASDAQ:ARVN) shareholders, who have seen the share price...

Yahoo | July 30, 2020

IPO Update: Nurix Therapeutics Prepares IPO Terms

Quick Take Nurix Therapeutics (NRIX) intends to raise $150 million from the sale of its common stock in an IPO, according to an amended registration statement. The company is developing drug candidates to treat various cancers. NRIX has significant collaboration partners and a top tier investor syndicate, but the firm...

Donovan Jones on Seeking Alpha | July 21, 2020

Did Hedge Funds Make The Right Call On Arvinas, Inc. (ARVN) ?

At the end of February we announced the arrival of the first US recession since 2009 and we predicted that the market will decline by at least 20% in (see why hell is coming). In these volatile markets we scrutinize hedge fund filings to get a reading on which direction each stock might be going. […]

Yahoo | July 20, 2020

Nurix Therapeutics Files For U.S. IPO

Quick Take Nurix Therapeutics (NRIX) has filed to raise $100 million in an IPO of its common stock, according to an S-1 registration statement. The company is developing small molecule-based treatments for blood cancers and immune system conditions. NRIX is a promising biopharma with substantial major pharma partnerships, but has...

Donovan Jones on Seeking Alpha | July 8, 2020

Arvinas Appoints Wendy Dixon, Ph.D., to its Board of Directors

NEW HAVEN, Conn., June 29, 2020 -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation,.

Yahoo | June 29, 2020

Arvinas to Present Virtually at the BMO 2020 Prescriptions for Success Healthcare Conference

NEW HAVEN, Conn., June 17, 2020 -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation,.

Yahoo | June 17, 2020

Here is What Hedge Funds Think About Arvinas, Inc. (ARVN)

In this article you are going to find out whether hedge funds think Arvinas, Inc. (NASDAQ:ARVN) is a good investment right now. We like to check what the smart money thinks first before doing extensive research on a given stock. Although there have been several high profile failed hedge fund picks, the consensus picks among […]

Yahoo | June 15, 2020

Arvinas Appoints Linda Bain to its Board of Directors

NEW HAVEN, Conn., June 11, 2020 -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation,.

Yahoo | June 11, 2020



Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!



Page generated in 0.6105 seconds.